The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Breakthrough Therapy Drugs-Global Market Insights and Sales Trends 2024
Synopsis
Breakthrough therapy drugs are intended to treat serious and life-threatening conditions. The breakthrough therapy is the designation given by FDA for the drugs when there is a preliminary clinical evidence indicates that the drug proves a substantial improvement over available drug treatment. Two factors determine the efficiency of breakthrough therapy drug, they are the magnitude of the treatment effect and observed clinical difference over the existed drug. The standard for breakthrough therapy drug is not same as standard drug approval because, in breakthrough therapy, morbidity and mortality considered for approval of the drug. They are meant to be administered by itself or in combinations. Breakthrough therapy drug development is cost effective due to faster approval of drugs on limited data from the FDA. Manufacturer of breakthrough therapy drugs has to develop additional post-marketing surveillance data for the other reimbursements and market access. Presently available breakthrough therapy medicinal products in the market belong to the treatment class of oncology, infectious diseases, cardiovascular conditions, etc. The designation is given when the drug is in 1st or 2nd stage of clinical trials.
The global Breakthrough Therapy Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Breakthrough Therapy Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Ambulatory Services,, are propelling Breakthrough Therapy Drugs market. Oncology, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Anti-Viral segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Breakthrough Therapy Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Breakthrough Therapy Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Breakthrough Therapy Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Breakthrough Therapy Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Breakthrough Therapy Drugs covered in this report include Merck, Pfizer, AbbVie, Bristol-Myers Squibb Company, Genentech, Gilead, Novartis and Vertex Pharmaceuticals Incorporated, etc.
The global Breakthrough Therapy Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
Pfizer
AbbVie
Bristol-Myers Squibb Company
Genentech
Gilead
Novartis
Vertex Pharmaceuticals Incorporated
Global Breakthrough Therapy Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Breakthrough Therapy Drugs market, Segment by Type:
Oncology
Anti-Viral
Neurology
Others
Global Breakthrough Therapy Drugs market, by Application
Hospitals
Clinics
Ambulatory Services
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Breakthrough Therapy Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Breakthrough therapy drugs are intended to treat serious and life-threatening conditions. The breakthrough therapy is the designation given by FDA for the drugs when there is a preliminary clinical evidence indicates that the drug proves a substantial improvement over available drug treatment. Two factors determine the efficiency of breakthrough therapy drug, they are the magnitude of the treatment effect and observed clinical difference over the existed drug. The standard for breakthrough therapy drug is not same as standard drug approval because, in breakthrough therapy, morbidity and mortality considered for approval of the drug. They are meant to be administered by itself or in combinations. Breakthrough therapy drug development is cost effective due to faster approval of drugs on limited data from the FDA. Manufacturer of breakthrough therapy drugs has to develop additional post-marketing surveillance data for the other reimbursements and market access. Presently available breakthrough therapy medicinal products in the market belong to the treatment class of oncology, infectious diseases, cardiovascular conditions, etc. The designation is given when the drug is in 1st or 2nd stage of clinical trials.
The global Breakthrough Therapy Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Breakthrough Therapy Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Ambulatory Services,, are propelling Breakthrough Therapy Drugs market. Oncology, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Anti-Viral segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Breakthrough Therapy Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Breakthrough Therapy Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Breakthrough Therapy Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Breakthrough Therapy Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Breakthrough Therapy Drugs covered in this report include Merck, Pfizer, AbbVie, Bristol-Myers Squibb Company, Genentech, Gilead, Novartis and Vertex Pharmaceuticals Incorporated, etc.
The global Breakthrough Therapy Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
Pfizer
AbbVie
Bristol-Myers Squibb Company
Genentech
Gilead
Novartis
Vertex Pharmaceuticals Incorporated
Global Breakthrough Therapy Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Breakthrough Therapy Drugs market, Segment by Type:
Oncology
Anti-Viral
Neurology
Others
Global Breakthrough Therapy Drugs market, by Application
Hospitals
Clinics
Ambulatory Services
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Breakthrough Therapy Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Breakthrough Therapy Drugs
1.1 Breakthrough Therapy Drugs Market Overview
1.1.1 Breakthrough Therapy Drugs Product Scope
1.1.2 Breakthrough Therapy Drugs Market Status and Outlook
1.2 Global Breakthrough Therapy Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Breakthrough Therapy Drugs Market Size by Region (2018-2029)
1.4 Global Breakthrough Therapy Drugs Historic Market Size by Region (2018-2023)
1.5 Global Breakthrough Therapy Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Breakthrough Therapy Drugs Market Size (2018-2029)
1.6.1 North America Breakthrough Therapy Drugs Market Size (2018-2029)
1.6.2 Europe Breakthrough Therapy Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Breakthrough Therapy Drugs Market Size (2018-2029)
1.6.4 Latin America Breakthrough Therapy Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Breakthrough Therapy Drugs Market Size (2018-2029)
2 Breakthrough Therapy Drugs Market by Type
2.1 Introduction
2.1.1 Oncology
2.1.2 Anti-Viral
2.1.3 Neurology
2.1.4 Others
2.2 Global Breakthrough Therapy Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Breakthrough Therapy Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Breakthrough Therapy Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Breakthrough Therapy Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Breakthrough Therapy Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Breakthrough Therapy Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Breakthrough Therapy Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Breakthrough Therapy Drugs Revenue Breakdown by Type (2018-2029)
3 Breakthrough Therapy Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Ambulatory Services
3.2 Global Breakthrough Therapy Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Breakthrough Therapy Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Breakthrough Therapy Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Breakthrough Therapy Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Breakthrough Therapy Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Breakthrough Therapy Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Breakthrough Therapy Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Breakthrough Therapy Drugs Revenue Breakdown by Application (2018-2029)
4 Breakthrough Therapy Drugs Competition Analysis by Players
4.1 Global Breakthrough Therapy Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Breakthrough Therapy Drugs as of 2022)
4.3 Date of Key Players Enter into Breakthrough Therapy Drugs Market
4.4 Global Top Players Breakthrough Therapy Drugs Headquarters and Area Served
4.5 Key Players Breakthrough Therapy Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Breakthrough Therapy Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Merck
5.1.1 Merck Profile
5.1.2 Merck Main Business
5.1.3 Merck Breakthrough Therapy Drugs Products, Services and Solutions
5.1.4 Merck Breakthrough Therapy Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Merck Recent Developments
5.2 Pfizer
5.2.1 Pfizer Profile
5.2.2 Pfizer Main Business
5.2.3 Pfizer Breakthrough Therapy Drugs Products, Services and Solutions
5.2.4 Pfizer Breakthrough Therapy Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Pfizer Recent Developments
5.3 AbbVie
5.3.1 AbbVie Profile
5.3.2 AbbVie Main Business
5.3.3 AbbVie Breakthrough Therapy Drugs Products, Services and Solutions
5.3.4 AbbVie Breakthrough Therapy Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Bristol-Myers Squibb Company Recent Developments
5.4 Bristol-Myers Squibb Company
5.4.1 Bristol-Myers Squibb Company Profile
5.4.2 Bristol-Myers Squibb Company Main Business
5.4.3 Bristol-Myers Squibb Company Breakthrough Therapy Drugs Products, Services and Solutions
5.4.4 Bristol-Myers Squibb Company Breakthrough Therapy Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Bristol-Myers Squibb Company Recent Developments
5.5 Genentech
5.5.1 Genentech Profile
5.5.2 Genentech Main Business
5.5.3 Genentech Breakthrough Therapy Drugs Products, Services and Solutions
5.5.4 Genentech Breakthrough Therapy Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Genentech Recent Developments
5.6 Gilead
5.6.1 Gilead Profile
5.6.2 Gilead Main Business
5.6.3 Gilead Breakthrough Therapy Drugs Products, Services and Solutions
5.6.4 Gilead Breakthrough Therapy Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Gilead Recent Developments
5.7 Novartis
5.7.1 Novartis Profile
5.7.2 Novartis Main Business
5.7.3 Novartis Breakthrough Therapy Drugs Products, Services and Solutions
5.7.4 Novartis Breakthrough Therapy Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Novartis Recent Developments
5.8 Vertex Pharmaceuticals Incorporated
5.8.1 Vertex Pharmaceuticals Incorporated Profile
5.8.2 Vertex Pharmaceuticals Incorporated Main Business
5.8.3 Vertex Pharmaceuticals Incorporated Breakthrough Therapy Drugs Products, Services and Solutions
5.8.4 Vertex Pharmaceuticals Incorporated Breakthrough Therapy Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Vertex Pharmaceuticals Incorporated Recent Developments
6 North America
6.1 North America Breakthrough Therapy Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Breakthrough Therapy Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Breakthrough Therapy Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Breakthrough Therapy Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Breakthrough Therapy Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Breakthrough Therapy Drugs Market Dynamics
11.1 Breakthrough Therapy Drugs Industry Trends
11.2 Breakthrough Therapy Drugs Market Drivers
11.3 Breakthrough Therapy Drugs Market Challenges
11.4 Breakthrough Therapy Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
